首页> 外文期刊>Therapeutic advances in hematology. >Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma
【24h】

Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma

机译:复发性低度非霍奇金淋巴瘤患者体外放射线启动放射免疫治疗

获取原文
       

摘要

The aim of this study was to evaluate the outcomes of priming salvage radioimmunotherapy (RIT) with a low dose of external beam radiotherapy (EBRT) in patients with relapsed low grade non-Hodgkin lymphoma (LG-NHL). Patients who received salvage RIT with or without 2 × 2 Gy EBRT between March 2009 and February 2013 were retrospectively reviewed at a single institution. Planning target volume (PTV) for EBRT was created by adding a 1–2 cm expansion to the gross tumor volume depending on the anatomical location. Kaplan?Meier method via log-rank was employed to analyze the endpoints freedom from progression (FFP) and overall survival (OS). We identified 22 patients who received salvage RIT without chemotherapy with a median follow up of 34 months. Of these, 9 (41%) patients were treated with EBRT immediately prior to RIT, and 13 (59%) received salvage RIT alone. Median FFP was not reached in patients who underwent combination treatment, while it was 9 months for patients treated with RIT alone (p = 0.02). OS for all patients at 36 months was 80.3% with no significant difference between the two groups (p = 0.88). On univariate analysis, the addition of EBRT was associated with improved FFP [hazard ratio (HR) = 4.17; 95% confidence interval (CI), 1.24–19.1; p = 0.02)]. No long term toxicities were reported in both groups. RIT outcomes and effects were improved with addition of low-dose EBRT immediately prior to it, in the treatment of relapsed LG-NHL with no additional toxicity. This study is hypothesis-generating and the findings should be validated in prospective studies.
机译:这项研究的目的是评估复发性低度非霍奇金淋巴瘤(LG-NHL)患者中低剂量外照射(EBRT)引发的抢救性放射免疫疗法(RIT)的结果。在2009年3月至2013年2月之间接受或不接受2×2 Gy EBRT的抢救性RIT患者在单个机构中进行回顾性检查。 EBRT的计划目标体积(PTV)是根据解剖位置在肿瘤总体积中增加1-2 cm的扩展而创建的。通过对数秩的Kaplan?Meier方法来分析终点的无进展(FFP)和总生存期(OS)。我们确定了22名未接受化疗的抢救性RIT患者,中位随访时间为34个月。在这些患者中,有9名(41%)患者在RIT之前即刻接受EBRT治疗,而13名(59%)仅接受挽救性RIT。接受联合治疗的患者未达到中位FFP,而仅接受RIT治疗的患者为9个月(p = 0.02)。所有患者在36个月时的OS为80.3%,两组之间无显着性差异(p = 0.88)。在单变量分析中,增加EBRT与改善FFP相关[危险比(HR)= 4.17; 95%置信区间(CI)为1.24-19.1; p = 0.02)]。两组均未报告长期毒性。在治疗复发的LG-NHL且无其他毒性的情况下,立即在其之前添加低剂量EBRT可改善RIT的结果和效果。该研究是假设产生的,其发现应在前瞻性研究中得到验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号